Synageva BioPharma Corp. is a biopharmaceutical company dedicated to discovering, developing and commercializing therapies for patients with rare conditions and high unmet medical need. The Company has developed a pipeline of novel therapeutics for underserved populations and has assembled a team with a proven record of bringing orphan therapies to patients. Synageva BioPharma has the ability to use its proprietary protein expression technology (SEP™), which due to its flexibility, scalability and consistency of end product is uniquely suited for the development and commercialization of personalized medicines for patients with rare diseases. Synageva’s lead program SBC-102 is an enzyme replacement therapy for lysosomal acid lipase (LAL) deficiency, also known as Wolman disease, cholesteryl ester storage disease (CESD), or Acid Lipase deficiency. LAL deficiency is a rare lysosomal storage disease (LSD) that is a progressive and often fatal condition. SBC-102 is in preclinical development and is designed to address the specific etiology of LAL deficiency by replacing the deficient or absent lysosomal acid lipase enzyme.

Synageva BioPharma was named AviGenics until 2008. Mr. Murphy founded AviGenics in 1996 and held various positions through 2004, including CEO, President, Chairman and Director. TASCF was raised after AviGenics was started, but acquired a position through the purchase of AviGenics shares in a private transaction and participation in several recent financings.